Collected from qualified healthy donors that meet baseline FDA 21 CFR 1271 requirements, industry’s first In Stock GMP-compliant Cryopreserved Leukopaks significantly decrease lead time
SaniSure, a global developer and manufacturer of single-use technology for the biopharmaceutical industry, announced today it has acquired GL Engineering (GLE) of East Hanover, New Jersey.
MilliporeSigma today announced the opening of its second Carlsbad, California-based facility, significantly expanding its CDMO footprint.
Arranta Bio (“Arranta”), a leading contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, today announced plans to establish contract manufacturing capacity for messenger RNA (mRNA) vaccines.
MicroCNX connectors are a critically important option for a range of bioprocessing, cell therapy and gene therapy workflows,.”Until now, cumbersome tube welding has been the only way to make sterile closed connections of very small-bore tubing. The MicroCNX connector represents a huge innovation for the industry.
Signature Biologics, LLC., today announced their expanded operations footprint to include a new 36,000 sq ft facility in Irving, TX. This newly constructed space mirrors Signature Biologics’ transparency in doing business with open floor plan and floor-to-ceiling views into its fully equipped manufacturing and R&D laboratory spaces.
Cytiva, a global life sciences leader, has partnered with Mycenax Biotech Inc, a leading biopharmaceutical CDMO company, to launch Taiwan’s first continuous bioprocessing lab.
Artiva Biotherapeutics, an oncology company specializing in primary allogeneic natural killer (NK) cell therapies to treat cancer, announced on Aug. 12, 2021 an expansion of its US presence with a new R&D and GMP manufacturing facility in San Diego, Calif., for cell therapies.
Tonix Pharmaceuticals Announces Groundbreaking Ceremony for Massachusetts R&D Facility to House the Advanced Development Center (ADC) for Vaccine Programs
A next-generation biomanufacturing plant incorporates multiple innovative technologies into a single facility, and therefore is built in half the construction time with approximately one half of the operating cost of a traditional plant. The next-generation biomanufacturing plant require a smaller manufacturing footprint and offer greater environmental benefits, including reduced consumption of water and energy and lower levels of carbon emissions.
Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, announced today the completion of a €47 million financing round (~US$55 million) to advance its lead program into clinical development. Andera Partners (formerly Edmond de Rothschild Investment Partners) led the financing round, joined by Pontifax, Bpifrance, Kurma Partners and IdInvest Partners.
Fujifilm acquires Irvine Scientific to maximize their synergy in its significant and growing bio-medical businesses. FujiFilm expects increased demand and needs of biopharmaceutical products and regenerative medicine therapy and is driving current rapid growth of the cell culture media market and estimates continued strong growth in the coming years.
